Base de dados : MEDLINE
Pesquisa : D02.033.455.250.700 [Categoria DeCS]
Referências encontradas : 47193 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4720 ir para página                         

  1 / 47193 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29339157
[Au] Autor:Teng Y; Pramanik S; Tateishi-Karimata H; Ohyama T; Sugimoto N
[Ad] Endereço:Frontier Institute for Biomolecular Engineering Research (FIBER), Konan University, 7-1-20 Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan.
[Ti] Título:Drastic stability change of X-X mismatch in d(CXG) trinucleotide repeat disorders under molecular crowding condition.
[So] Source:Biochem Biophys Res Commun;496(2):601-607, 2018 02 05.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The trinucleotide repeat d(CXG) (X = A, C, G or T) is the most common sequence causing repeat expansion disorders. The formation of non-canonical structures, such as hairpin structures with X-X mismatches, has been proposed to affect gene expression and regulation, which are important in pathological studies of these devastating neurological diseases. However, little information is available regarding the thermodynamics of the repeat sequence under crowded cellular conditions where many non-canonical structures such as G-quadruplexes are highly stabilized, while duplexes are destabilised. In this study, we investigated the different stabilities of X-X mismatches in the context of internal d(CXG) self-complementary sequences in an environment with a high concentration of cosolutes to mimic the crowding conditions in cells. The stabilities of full-matched duplexes and duplexes with A-A, G-G, and T-T mismatched base pairs under molecular crowding conditions were notably decreased compared to under dilute conditions. However, the stability of the DNA duplex with a C-C mismatch base pair was only slightly destabilised. Investigating different stabilities of X-X mismatches in d(CXG) sequences is important for improving our understanding of the formation and transition of multiple non-canonical structures in trinucleotide repeat diseases, and may provide insights for pathological studies and drug development.
[Mh] Termos MeSH primário: Pareamento Incorreto de Bases
DNA/genética
Repetições de Trinucleotídeos
[Mh] Termos MeSH secundário: Sequência de Bases
DNA/química
Quadruplex G
Conformação de Ácido Nucleico
Polietilenoglicóis/química
Termodinâmica
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
30IQX730WE (Polyethylene Glycols); 9007-49-2 (DNA)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE


  2 / 47193 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461099
[Au] Autor:Alaaeldin E; Abu Lila AS; Ando H; Fukushima M; Huang CL; Wada H; Sarhan HA; Khaled KA; Ishida T
[Ad] Endereço:Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, 1-78-1, Sho-machi, Tokushima 770-8505, Japan; Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
[Ti] Título:Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules.
[So] Source:J Control Release;255:210-217, 2017 Jun 10.
[Is] ISSN:1873-4995
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Many therapeutic strategies have been applied in efforts to conquer the development and/or progression of cancer. The combination of chemotherapy and an RNAi-based approach has proven to be an efficient anticancer therapy. However, the feasibility of such a therapeutic strategy has been substantially restricted either by the failure to achieve the efficient delivery of RNAi molecules to tumor tissue or by the immunostimulatory response triggered by RNAi molecules. In this study, therefore, we intended to investigate the efficacy of using liposomal oxaliplatin (liposomal l-OHP) to guarantee the efficient delivery of RNAi molecules, namely shRNA against thymidylate synthase (TS shRNA) complexed with cationic liposome (TS shRNA-lipoplex), to solid tumors, and to suppress the immunostimulatory effect of RNAi molecules, TS shRNA, following intravenous administration. Herein, we describe how liposomal l-OHP enhanced the intra-tumor accumulation of TS shRNA-lipoplex and significantly reduced the immunostimulatory response triggered by TS shRNA. Consequently, such enhanced accumulation of TS shRNA-lipoplex along with the cytotoxic effect of liposomal l-OHP led to a remarkable tumor growth suppression (compared to mono-therapy) following systemic administration. Our results, therefore, may have important implications for the provision of a safer and more applicable combination therapy of RNAi molecules and anti-cancer agents that can produce a more reliable anti-tumor effect.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Neoplasias/terapia
Compostos Organoplatínicos/administração & dosagem
RNA Interferente Pequeno/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/química
Antineoplásicos/farmacocinética
Antineoplásicos/uso terapêutico
Linhagem Celular Tumoral
Citocinas/metabolismo
Seres Humanos
Lipossomos
Masculino
Camundongos Endogâmicos BALB C
Camundongos Nus
Neoplasias/genética
Neoplasias/metabolismo
Compostos Organoplatínicos/química
Compostos Organoplatínicos/farmacocinética
Compostos Organoplatínicos/uso terapêutico
Polietilenoglicóis/química
Interferência de RNA
RNA Interferente Pequeno/química
RNA Interferente Pequeno/farmacocinética
RNA Interferente Pequeno/uso terapêutico
Timidilato Sintase/genética
Distribuição Tecidual
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Cytokines); 0 (Liposomes); 0 (Organoplatinum Compounds); 0 (RNA, Small Interfering); 04ZR38536J (oxaliplatin); 30IQX730WE (Polyethylene Glycols); EC 2.1.1.45 (Thymidylate Synthase)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  3 / 47193 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27774855
[Au] Autor:Yin S; Xia Y; Jia Q; Hou ZS; Zhang N
[Ad] Endereço:a Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, College of Chemistry, Chemical Engineering and Materials Science , Shandong Normal University , Jinan , China.
[Ti] Título:Preparation and properties of biomedical segmented polyurethanes based on poly(ether ester) and uniform-size diurethane diisocyanates.
[So] Source:J Biomater Sci Polym Ed;28(1):119-138, 2017 01.
[Is] ISSN:1568-5624
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study describes the preparation and properties of a novel aliphatic cost-effective segmented polyurethanes (SPUs) based on poly(ether ester) (poly-(ε-caprolactone-co-l-lactide)-poly(ethylene glycol)-poly-(ε-caprolactone-co-l-lactide), PECLA) and uniform-size diurethane diisocyanates (HDI-BDO-HDI). PECLA was synthesized via bulk ring-opening polymerization with poly(ethylene glycol) (PEG) as an initiator and ε-caprolactone, l-lactide as monomers. By chain extension of PECLA diol with HDI-BDO-HDI, three SPUs with different hydrophilic segments content and hard segments content were obtained. The chemical structures of the chain extender, PECLA and SPUs were confirmed by H NMR, C NMR, FT-IR, HR-TOF-MS and GPC. The influences of PEG content and uniform-size hard segments on in vitro degradability and mechanical properties of SPU films were researched. Similar thermostability observed in TGA curves of SPU films indicated that the hard segments and PEG content had little influence on the thermostability. The formation of microsphase-separated morphologies, which were demonstrated by the results of DSC and XRD, and physical-linking (H-bonds) network structures led to better mechanical properties of SPU films (ultimate stress: 23.1-17.9 MPa; elongation at break: 840-1130%). The results of water absorption and water contact angle showed that the bulk and surface hydrophilicity were closely related with the hydrophilic PEG content in SPU backbone. And the water absorption being less than 10 wt% indicated that the SPU films had low swelling property. In vitro hydrolytic degradation studies showed that the time of the SPU films becoming fragments was 34-19 days and the degradation rate increased with the increasing content of hydrophilic segments in SPUs, indicating that the degradation rate of SPU films could be controlled by adjusting PEG content. Cytotoxicity test of film extracts were conducted using L929 cells, and the relative growth rate exceeded 90% after incubation for 24, 48 and 72 h, showing excellent cytocompatibility. The acceptable mechanical properties, controllable biodegradability and excellent cytocompatibility of the polyurethanes can make them good candidates for further biomedical applications.
[Mh] Termos MeSH primário: Materiais Biocompatíveis/química
Éter/química
Poliésteres/química
Polietilenoglicóis/química
Poliuretanos/química
[Mh] Termos MeSH secundário: Adsorção
Animais
Materiais Biocompatíveis/toxicidade
Bovinos
Linhagem Celular
Estabilidade de Medicamentos
Fenômenos Mecânicos
Camundongos
Soroalbumina Bovina/química
Temperatura Ambiente
Água/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Polyesters); 0 (Polyurethanes); 0 (poly(epsilon-caprolactone-co-lactide)-poly(ethylene glycol)); 059QF0KO0R (Water); 0F5N573A2Y (Ether); 27432CM55Q (Serum Albumin, Bovine); 30IQX730WE (Polyethylene Glycols)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161104
[St] Status:MEDLINE


  4 / 47193 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29489686
[Au] Autor:Shi X; Yu S; Wang F; Zhao Q; Xu H; Li B
[Ad] Endereço:Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University.
[Ti] Título:A gastrointestinal stromal tumor with acute bleeding: Management and nursing.
[So] Source:Medicine (Baltimore);97(9):e9874, 2018 Mar.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors involving the gastrointestinal tract. A small percentage of GISTs may cause acute gastrointestinal bleeding, which requires urgent surgical intervention. PATIENT CONCERNS: In this case report, we present a 62-year-old male patient with who was hospitalized due to acute bleeding. DIAGNOSES: The patient was diagnosed as GIST with low risk. INTERVENTIONS: The patient was treated endoscopically with polidocanol sclerotherapy. OUTCOMES: The mass was removed completely, and the patient was discharged at day 9 after operation. LESSONS: This case indicates that GIST can present as massive upper gastrointestinal bleeding and urgent endoscopic sclerotherapy can be life-saving. The endoscopical intervention may be a good alternative for emergency.
[Mh] Termos MeSH primário: Hemorragia Gastrointestinal/etiologia
Neoplasias Gastrointestinais/complicações
Tumores do Estroma Gastrointestinal/complicações
[Mh] Termos MeSH secundário: Hemorragia Gastrointestinal/terapia
Neoplasias Gastrointestinais/terapia
Tumores do Estroma Gastrointestinal/terapia
Seres Humanos
Masculino
Meia-Idade
Polietilenoglicóis/uso terapêutico
Soluções Esclerosantes/uso terapêutico
Escleroterapia/métodos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sclerosing Solutions); 0AWH8BFG9A (polidocanol); 30IQX730WE (Polyethylene Glycols)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180301
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009874


  5 / 47193 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28453702
[Au] Autor:Monk BJ; Brady MF; Aghajanian C; Lankes HA; Rizack T; Leach J; Fowler JM; Higgins R; Hanjani P; Morgan M; Edwards R; Bradley W; Kolevska T; Foukas P; Swisher EM; Anderson KS; Gottardo R; Bryan JK; Newkirk M; Manjarrez KL; Mannel RS; Hershberg RM; Coukos G
[Ad] Endereço:Arizona Oncology (US Oncology Network), University of Arizona, College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, Phoenix.
[Ti] Título:A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
[So] Source:Ann Oncol;28(5):996-1004, 2017 May 01.
[Is] ISSN:1569-8041
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background: A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of motolimod-a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses-combined with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death. Patients and methods: Women with ovarian, fallopian tube, or primary peritoneal carcinoma were randomized 1 : 1 to receive PLD in combination with blinded motolimod or placebo. Randomization was stratified by platinum-free interval (≤6 versus >6-12 months) and Gynecologic Oncology Group (GOG) performance status (0 versus 1). Treatment cycles were repeated every 28 days until disease progression. Results: The addition of motolimod to PLD did not significantly improve overall survival (OS; log rank one-sided P = 0.923, HR = 1.22) or progression-free survival (PFS; log rank one-sided P = 0.943, HR = 1.21). The combination was well tolerated, with no synergistic or unexpected serious toxicity. Most patients experienced adverse events of fatigue, anemia, nausea, decreased white blood cells, and constipation. In pre-specified subgroup analyses, motolimod-treated patients who experienced injection site reactions (ISR) had a lower risk of death compared with those who did not experience ISR. Additionally, pre-treatment in vitro responses of immune biomarkers to TLR8 stimulation predicted OS outcomes in patients receiving motolimod on study. Immune score (tumor infiltrating lymphocytes; TIL), TLR8 single-nucleotide polymorphisms, mutational status in BRCA and other DNA repair genes, and autoantibody biomarkers did not correlate with OS or PFS. Conclusions: The addition of motolimod to PLD did not improve clinical outcomes compared with placebo. However, subset analyses identified statistically significant differences in the OS of motolimod-treated patients on the basis of ISR and in vitro immune responses. Collectively, these data may provide important clues for identifying patients for treatment with immunomodulatory agents in novel combinations and/or delivery approaches. Trial registration: Clinicaltrials.gov, NCT 01666444.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Recidiva Local de Neoplasia/tratamento farmacológico
Neoplasias Epiteliais e Glandulares/tratamento farmacológico
Neoplasias Ovarianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/administração & dosagem
Adulto
Idoso
Idoso de 80 Anos ou mais
Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia
Benzazepinas/administração & dosagem
Intervalo Livre de Doença
Método Duplo-Cego
Doxorrubicina/administração & dosagem
Doxorrubicina/análogos & derivados
Seres Humanos
Imunidade Inata/efeitos dos fármacos
Estimativa de Kaplan-Meier
Meia-Idade
Recidiva Local de Neoplasia/mortalidade
Neoplasias Epiteliais e Glandulares/mortalidade
Neoplasias Ovarianas/mortalidade
Polietilenoglicóis/administração & dosagem
Modelos de Riscos Proporcionais
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Benzazepines); 0 (VTX-2337); 0 (liposomal doxorubicin); 30IQX730WE (Polyethylene Glycols); 80168379AG (Doxorubicin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1093/annonc/mdx049


  6 / 47193 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29182213
[Au] Autor:Zeighami S; Mirmohammadrezaei S; Safi M; Falahchai SM
[Ad] Endereço:Assistant Professor, Dental Research Center, Dentistry Research Institute and Department of Prosthodontics, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.
[Ti] Título:The Effect of Core and Veneering Design on the Optical Properties of Polyether Ether Ketone.
[So] Source:Eur J Prosthodont Restor Dent;25(4):201-208, 2017 Dec 01.
[Is] ISSN:0965-7452
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study aimed to evaluate the effect of core shade and core and veneering thickness on color parameters and translucency of polyether ether ketone (PEEK). Sixty PEEK discs (0.5 and 1 mm in thickness) with white and dentine shades were veneered with A2 shade indirect composite resin with 0.5, 1 and 1.5 mm thickness (n=5). Cores without the veneering material served as controls for translucency evaluation. Color parameters were measured by a spectroradiometer. Color difference (ΔE00) and translucency parameters (TP) were computed. Data were analyzed using one-way ANOVA and Tukey's test (for veneering thickness) and independent t-test (for core shade and thickness) via SPSS 20.0 (p⟨0.05). Regarding the veneering thickness, white cores of 0.5 mm thickness showed significant differences in all color parameters. In white cores of 1 mm thickness and dentine cores of 0.5 and 1 mm thickness, there were statistically significant differences only in L∗, a∗ and h∗. The mean TP was significantly higher in all white cores of 1 mm thickness than dentine cores of 1 mm. Considering ΔE00=3.7 as clinically unacceptable, only three groups had higher mean ΔE00 values. Core shade, core thickness, and the veneering thickness affected the color and translucency of PEEK restorations.
[Mh] Termos MeSH primário: Materiais Biocompatíveis
Planejamento de Prótese Dentária
Facetas Dentárias
Cetonas
Polietilenoglicóis
Pigmentação em Prótese
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Ketones); 30IQX730WE (Polyethylene Glycols); 31694-16-3 (polyetheretherketone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1922/EJPRD_01720Zeighami08


  7 / 47193 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29396378
[Au] Autor:Kori S; Parmar A; Goyal J; Sharma S
[Ad] Endereço:Institute of Forensic Science & Criminology, Panjab University, Chandigarh 160 014, India.
[Ti] Título:Cloud point extraction coupled with microwave-assisted back-extraction (CPE-MABE) for determination of Eszopiclone (Z-drug) using UV-Visible, HPLC and mass spectroscopic (MS) techniques: Spiked and in vivo analysis.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1074-1075:129-138, 2018 Feb 01.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A procedure for the determination of Eszopiclone (ESZ) from complex matrices i.e. in vitro (spiked matrices), as well as in vivo (mice model) was developed using cloud point extraction coupled with microwave-assisted back-extraction (CPE-MABE). Analytical measurements have been carried using UV-Visible, HPLC and MS techniques. The proposed method has been validated according to ICH guidelines and legitimate reproducible and reliability of protocol is assessed through intraday and inter-day precision <3.61% and <4.70%, respectively. Limit of detection has been obtained as 0.083µg/mL and 0.472µg/mL respectively, for HPLC and UV-Visible techniques, corresponding to assessed linearity range. The coaservate phase in CPE was back extracted under microwaves exposure, with isooctane at pre-concentration factor ~50 when 5mL of sample solution was pre-concentrated to 0.1mL. Under optimized conditions i.e. Aqueous-Triton X-114 4% (w/v), pH4.0, NaCl 4% (w/v) and equilibrium temperature of 45°C for 20min, average extraction recovery has been obtained between 89.8 and 99.2% and 84.0-99.2% from UV-Visible and HPLC analysis, respectively. The method has been successfully applied to the pharmacokinetic estimation (post intraperitoneal administration) of ESZ in mice. MS analysis precisely depicted the presence of active N­desmethyl zopiclone in impales as well as in mice plasma.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Zopiclona/análise
Espectrometria de Massas/métodos
[Mh] Termos MeSH secundário: Animais
Fracionamento Químico
Zopiclona/química
Zopiclona/isolamento & purificação
Zopiclona/farmacocinética
Seres Humanos
Concentração de Íons de Hidrogênio
Limite de Detecção
Modelos Lineares
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Micro-Ondas
Leite/química
Polietilenoglicóis
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
30IQX730WE (Polyethylene Glycols); 9036-19-5 (Nonidet P-40); UZX80K71OE (Eszopiclone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180204
[St] Status:MEDLINE


  8 / 47193 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29361623
[Au] Autor:Nagashima Y; Chijimatsu H; Furuya K; Kondo J; Maeda Y; Somura H; Takemoto N; Yahara N; Abe T; Hayashi H; Kubo H; Yamamoto S; Nagano H
[Ad] Endereço:Dept. of Surgery, Kanmon Medical Center.
[Ti] Título:[Effect of Pegfilgrastim Primary Prophylactic Administration on Relative Dose Intensity(RDI)in Postoperative Adjuvant Chemotherapy(TC Therapy)for Breast Cancer - A Single-Center, Retrospective Study].
[So] Source:Gan To Kagaku Ryoho;44(13):2087-2090, 2017 Dec.
[Is] ISSN:0385-0684
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:This study assessed the effect of pegfilgrastim in patients with early stage breast cancer who were receiving docetaxel and cyclophosphamide(TC)therapy(75mg/m / 2 docetaxel plus 600 mg/m2 cyclophosphamide). In total, 17 patients who were to receive 4 planned cycles of TC therapy every 3 weeks were included in this study. Of the 17 patients, 10 who received pegfilgrastim after January 2016 formed the Peg-G group and 7 who did not receive pegfilgrastim until December 2015 formed the control group. We observed a high successful execution rate and relative dose intensity(RDI)with docetaxel in both groups. The successful execution rates were 100% in the Peg-G group and 42.8% in the control group. The RDI was 86.5%(65.4-100%)in the Peg-G group and 52.5%(48.0-58.0%)in the control group. This study showed that the use of pegfilgrastim results in a high successful execution rate and RDI in patients with early stage breast cancer undergoing TC therapy.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Neoplasias da Mama/tratamento farmacológico
Ciclofosfamida/efeitos adversos
Filgrastim/uso terapêutico
Neutropenia/prevenção & controle
Polietilenoglicóis/uso terapêutico
Taxoides/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Idoso
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias da Mama/cirurgia
Quimioterapia Adjuvante
Ciclofosfamida/administração & dosagem
Filgrastim/administração & dosagem
Seres Humanos
Meia-Idade
Polietilenoglicóis/administração & dosagem
Estudos Retrospectivos
Taxoides/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Taxoids); 15H5577CQD (docetaxel); 30IQX730WE (Polyethylene Glycols); 3A58010674 (pegfilgrastim); 8N3DW7272P (Cyclophosphamide); PVI5M0M1GW (Filgrastim)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE


  9 / 47193 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29406050
[Au] Autor:Cheung CC; Constantine M; Ahmadi A; Shiau C; Chen LYC
[Ad] Endereço:Division of Hematology, Gordon and Leslie Diamond Health Care Centre, University of British Columbia, Vancouver, British Columbia, Canada.
[Ti] Título:Lymphocyte-Variant Hypereosinophilic Syndrome With Eosinophilic Myocarditis Treated With Steroids and Pegylated Interferon Alfa-2a.
[So] Source:Am J Med Sci;355(2):201-202, 2018 Feb.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Angiografia Coronária
Eletrocardiografia
Síndrome Hipereosinofílica
Interferon-alfa/administração & dosagem
Imagem por Ressonância Magnética
Miocardite
Polietilenoglicóis/administração & dosagem
Prednisona/administração & dosagem
[Mh] Termos MeSH secundário: Eosinófilos/metabolismo
Feminino
Seres Humanos
Síndrome Hipereosinofílica/sangue
Síndrome Hipereosinofílica/diagnóstico por imagem
Síndrome Hipereosinofílica/tratamento farmacológico
Síndrome Hipereosinofílica/fisiopatologia
Contagem de Leucócitos
Linfócitos/metabolismo
Meia-Idade
Miocardite/sangue
Miocardite/diagnóstico por imagem
Miocardite/tratamento farmacológico
Miocardite/fisiopatologia
Proteínas Recombinantes/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Interferon-alpha); 0 (Recombinant Proteins); 30IQX730WE (Polyethylene Glycols); Q46947FE7K (peginterferon alfa-2a); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE


  10 / 47193 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27770562
[Au] Autor:Wang C; Tong X; Jiang X; Yang F
[Ad] Endereço:Department of Bioengineering, Stanford University, Stanford, California, 94305.
[Ti] Título:Effect of matrix metalloproteinase-mediated matrix degradation on glioblastoma cell behavior in 3D PEG-based hydrogels.
[So] Source:J Biomed Mater Res A;105(3):770-778, 2017 03.
[Is] ISSN:1552-4965
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Glioblastoma (GBM) is the most common and aggressive form of primary brain tumor with median survival of 12 months. To improve clinical outcomes, it is critical to develop in vitro models that support GBM proliferation and invasion for deciphering tumor progression and screening drug candidates. A key hallmark of GBM cells is their extreme invasiveness, a process mediated by matrix metalloproteinase (MMP)-mediated degradation of the extracellular matrix. We recently reported the development of a MMP-degradable, poly(ethylene-glycol)-based hydrogel platform for culturing GBM cells. In the present study, we modulated the percentage of MMP-degradable crosslinks in 3D hydrogels to analyze the effects of MMP-degradability on GBM fates. Using an immortalized GBM cell line (U87) as a model cell type, our results showed that MMP-degradability was not required for supporting GBM proliferation. All hydrogel formulations supported robust GBM proliferation, up to 10 fold after 14 days. However, MMP-degradability was essential for facilitating tumor spreading, and 50% MMP-degradable hydrogels were sufficient to enable both robust tumor cell proliferation and spreading in 3D. The findings of this study highlight the importance of modulating MMP-degradability in engineering 3D in vitro brain cancer models and may be applied for engineering in vitro models for other cancer types. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 770-778, 2017.
[Mh] Termos MeSH primário: Neoplasias Encefálicas/metabolismo
Matriz Extracelular/química
Glioblastoma/metabolismo
Hidrogéis/química
Polietilenoglicóis/química
[Mh] Termos MeSH secundário: Neoplasias Encefálicas/patologia
Linhagem Celular Tumoral
Gelatinases
Glioblastoma/patologia
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Hydrogels); 30IQX730WE (Polyethylene Glycols); EC 3.4.24.- (Gelatinases); U076Q6Q621 (polyethylene glycol 1000)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161023
[St] Status:MEDLINE
[do] DOI:10.1002/jbm.a.35947



página 1 de 4720 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde